Tags

Type your tag names separated by a space and hit enter

Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS.
Postgrad Med. 2009 Mar; 121(2):119-24.PM

Abstract

BACKGROUND

Symptoms of irritable bowel syndrome (IBS) can have a profound impact on emotional health and quality of life, and current treatments are sometimes unsatisfactory for patients facing this lifelong disease. Probiotics, which can normalize gastrointestinal microflora, may alleviate symptoms of IBS.

OBJECTIVE

This preliminary controlled study was conducted to evaluate the effects of the probiotic Bacillus coagulans GBI-30, 6086 on IBS symptoms.

METHODS

This was a randomized, double-blind, parallel-group, placebo-controlled clinical trial involving 44 subjects who received either placebo or B coagulans GBI-30, 6086 once a day for 8 weeks. Self-assessments of the severity of IBS symptoms (abdominal pain and bloating) were recorded every day for 8 weeks. Because baseline values were significantly different between the 2 study groups, within-group analysis was conducted.

RESULTS

Improvements from baseline abdominal pain and bloating scores in the B coagulans GBI-30, 6086 group were statistically significant for all 7 weekly comparisons (P < 0.01). In the placebo group, only changes in abdominal pain scores at weeks 6 and 8 achieved statistical significance (P < 0.05). No treatment-related adverse events or serious adverse events were reported during the 8-week study period.

CONCLUSIONS

Preliminary data suggest that the patented B coagulans GBI-30, 6086 probiotic may be a safe and effective option for the relief of abdominal pain and bloating for patients with IBS. Larger, extended trials are needed to verify these results.

Authors+Show Affiliations

Research Testing Laboratories, Great Neck, NY, USA. pedipod3@aol.com

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

19332970

Citation

Hun, Larysa. "Bacillus Coagulans Significantly Improved Abdominal Pain and Bloating in Patients With IBS." Postgraduate Medicine, vol. 121, no. 2, 2009, pp. 119-24.
Hun L. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med. 2009;121(2):119-24.
Hun, L. (2009). Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgraduate Medicine, 121(2), 119-24. https://doi.org/10.3810/pgm.2009.03.1984
Hun L. Bacillus Coagulans Significantly Improved Abdominal Pain and Bloating in Patients With IBS. Postgrad Med. 2009;121(2):119-24. PubMed PMID: 19332970.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. A1 - Hun,Larysa, PY - 2009/4/1/entrez PY - 2009/4/1/pubmed PY - 2009/4/22/medline SP - 119 EP - 24 JF - Postgraduate medicine JO - Postgrad Med VL - 121 IS - 2 N2 - BACKGROUND: Symptoms of irritable bowel syndrome (IBS) can have a profound impact on emotional health and quality of life, and current treatments are sometimes unsatisfactory for patients facing this lifelong disease. Probiotics, which can normalize gastrointestinal microflora, may alleviate symptoms of IBS. OBJECTIVE: This preliminary controlled study was conducted to evaluate the effects of the probiotic Bacillus coagulans GBI-30, 6086 on IBS symptoms. METHODS: This was a randomized, double-blind, parallel-group, placebo-controlled clinical trial involving 44 subjects who received either placebo or B coagulans GBI-30, 6086 once a day for 8 weeks. Self-assessments of the severity of IBS symptoms (abdominal pain and bloating) were recorded every day for 8 weeks. Because baseline values were significantly different between the 2 study groups, within-group analysis was conducted. RESULTS: Improvements from baseline abdominal pain and bloating scores in the B coagulans GBI-30, 6086 group were statistically significant for all 7 weekly comparisons (P < 0.01). In the placebo group, only changes in abdominal pain scores at weeks 6 and 8 achieved statistical significance (P < 0.05). No treatment-related adverse events or serious adverse events were reported during the 8-week study period. CONCLUSIONS: Preliminary data suggest that the patented B coagulans GBI-30, 6086 probiotic may be a safe and effective option for the relief of abdominal pain and bloating for patients with IBS. Larger, extended trials are needed to verify these results. SN - 1941-9260 UR - https://www.unboundmedicine.com/medline/citation/19332970/Bacillus_coagulans_significantly_improved_abdominal_pain_and_bloating_in_patients_with_IBS_ L2 - https://www.tandfonline.com/doi/full/10.3810/pgm.2009.03.1984 DB - PRIME DP - Unbound Medicine ER -